293 related articles for article (PubMed ID: 32523115)
21. Interleukin-15: new kid on the block for antitumor combination therapy.
Van den Bergh JM; Van Tendeloo VF; Smits EL
Cytokine Growth Factor Rev; 2015 Feb; 26(1):15-24. PubMed ID: 25306466
[TBL] [Abstract][Full Text] [Related]
22. Th1 cytokine-based immunotherapy for cancer.
Xu HM
Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):482-94. PubMed ID: 25308358
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
24. Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
Sabry M; Lowdell MW
Stem Cells Transl Med; 2020 Sep; 9(9):974-984. PubMed ID: 32416056
[TBL] [Abstract][Full Text] [Related]
25. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
Smyth MJ; Swann J; Kelly JM; Cretney E; Yokoyama WM; Diefenbach A; Sayers TJ; Hayakawa Y
J Exp Med; 2004 Nov; 200(10):1325-35. PubMed ID: 15545356
[TBL] [Abstract][Full Text] [Related]
26. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy.
Weber R; Groth C; Lasser S; Arkhypov I; Petrova V; Altevogt P; Utikal J; Umansky V
Cell Immunol; 2021 Jan; 359():104254. PubMed ID: 33296753
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
[TBL] [Abstract][Full Text] [Related]
28. Bench to bedside: NK cells and control of metastasis.
Krasnova Y; Putz EM; Smyth MJ; Souza-Fonseca-Guimaraes F
Clin Immunol; 2017 Apr; 177():50-59. PubMed ID: 26476139
[TBL] [Abstract][Full Text] [Related]
29. Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside.
Woan KV; Miller JS
Cancer Immunol Res; 2019 Nov; 7(11):1742-1747. PubMed ID: 31676567
[TBL] [Abstract][Full Text] [Related]
30. Common gamma chain cytokines in combinatorial immune strategies against cancer.
Pulliam SR; Uzhachenko RV; Adunyah SE; Shanker A
Immunol Lett; 2016 Jan; 169():61-72. PubMed ID: 26597610
[TBL] [Abstract][Full Text] [Related]
31. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
[TBL] [Abstract][Full Text] [Related]
32. IL-21 Signaling in the Tumor Microenvironment.
Chabab G; Bonnefoy N; Lafont V
Adv Exp Med Biol; 2020; 1240():73-82. PubMed ID: 32060889
[TBL] [Abstract][Full Text] [Related]
33. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
34. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
[TBL] [Abstract][Full Text] [Related]
35. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.
Ochoa MC; Minute L; Rodriguez I; Garasa S; Perez-Ruiz E; Inogés S; Melero I; Berraondo P
Immunol Cell Biol; 2017 Apr; 95(4):347-355. PubMed ID: 28138156
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
37. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
38. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
39. Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells.
Littwitz-Salomon E; Dittmer U; Sutter K
Retrovirology; 2016 Nov; 13(1):77. PubMed ID: 27821119
[TBL] [Abstract][Full Text] [Related]
40. Stimulating natural killer cells to protect against cancer: recent developments.
Gillgrass A; Ashkar A
Expert Rev Clin Immunol; 2011 May; 7(3):367-82. PubMed ID: 21595603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
